Supplement 6

Kaplan-Meier Method

Table of Contents

- 6.1 Introduction to the Kaplan-Meier Method Used
- 6.2 Outcomes Affecting >5% of Patients for Time-to-recovery and Hazard Ratio (P<0.050)
- 6.3 Full Table for Kaplan-Meier Estimates in Patients with a WURSS-44 Q1 Score of 4-7 at Baseline
 - 6.4 Kaplan-Meier Curves of Primary Outcome
- 6.5 Kaplan-Meier Curves for Secondary Symptoms with Duration 0-5 days and 6-10 days at Screening (P≤0.050)

Introduction to the Kaplan-Meier Method Used

The Kaplan-Meier (KM) Method is utilized to estimate the time-to-recovery (days) applied to the 43 items/symptoms listed in WURSS-44 for primary and secondary efficacy outcomes. "Recovery" is defined as having 3 consecutive days of no symptom, or a score of '0' on the WURSS-44 scale. The first day of the 3-day recovery is used to compute days-to-recovery.

The time-to-recovery values in the primary endpoint were assessed with the KM method, and the difference between the Treatment and Control groups were assessed with the log-rank test, stratified by symptom duration days. In calculating the time-to-recovery for the secondary symptoms, the KM Method and log-rank tests were applied in the same way as for the primary outcome.

'Day 1' is the Baseline, defined as the day of first-use of the treatment device. Knowing that there is a roughly 2 days delay in receiving treatment. Symptom duration days can be interpreted as having added a median of 2 days to the 0-5 days strata duration, the equivalent of 0-7 days. Similarly, the 6-10 day symptom duration stratum is equivalent to 8-12 days at baseline.

Patients who did not achieve recovery at the end of the 30-day assessment period were censored. This also included patients whose 3-day results were incomplete.

In this Supplement section, we include a table of significant outcomes for WURSS-44 secondary endpoints (Supplement 6.2, also presented as Table 3), the full table for all the WURSS-44 items (Supplement 6.3) as well as the KM curves for the Primary (Supplement 6.4) and Secondary outcomes (Supplement 6.5) with significance ($P \le 0.05$).

Supplement 6.2

Outcomes Affecting >5% of Patients for Time-to-recovery and Hazard Ratio (P<0.050)

				Кар	lan-Meier	·	·		Cox Pr	oportional Hazards	3
	Days with					Median		KM			
Symptom	Symptoms at Screening	Treatment _	Total	N Recovered	Censored	Days to Recovery	95% CI	Log-rank P-value	Hazard Ratio	95% CI	Cox P-value
					***************************************	y	3575 C.			3070 C.	
Patients with 0-10 D	ays Symptom Di	uration (all at Ba	seline)								
Sinus pain	0 to 10	Treatment	39		4		(8, 13)		2.001	(1.203, 3.328)	0.008
		Control Total	42 81		12 16		(9, 25)				
						_					
Chest congestion	0 to 10	Treatment Control	43 35		5 13		(9, 18) (17, 30)		1.878	(1.105, 3.193)	0.02
		Total	78		18		(17, 50)				
Body aches	0 to 10	Treatment	60	52	8	12	(0.15)	0.019	1.652	(1.084, 2.519)	0.02
Body acries	0 to 10	Control	59		20		(9,15) (12, 20)		1.052	(1.064, 2.519)	0.02
		Total	119	119	28						
Think clearly	0 to 10	Treatment	44	. 34	10	11	(9, 15)	0.020	1.893	(1.013, 3.248)	0.021
,		Control	41		18		(12, 30)			,,,	
		Total	85	57	28	<u>10</u>					
Ear discomfort	0 to 10	Treatment	24	21	3	12.5	(8, 17)	0.023	2.325	(1.104, 4.893)	0.026
		Control	21		10	-	(12, 36)				
		Total	45	32	13	<u>13.5</u>					
Sinus drainage	0 to 10	Treatment	28	22	6	12	(10, 17)	0.026	2.14	(1.088, 4.203)	0.028
		Control	27		12	-	(10, 36)				
		Total	55	37	18	<u>11</u>					
Headache	0 to 10	Treatment	67	53	14	14	(11, 20)	0.031	1.586	(1.036, 2.429)	0.034
		Control Total	61 128		25 39		(14, 28)				
		TOLAI	120	09	39	<u> 7</u>					
Coughing up stuff	0 to 10	Treatment	27		2		(10, 20)		1.817	(1.013, 3.261)	0.045
		Control Total	32 59		11 13		(14, 27)				
		TOTAL	35	40	15						
Sneezing	0 to 10	Treatment	33		4		(9, 18)		1.92	(1.064, 3.467)	0.030
		Control Total			8 12		(10, 24)				
		Total				. -					
Patients with 0-5 Da	ys Symptom Dui	ration									
Headache	0 to 5	Treatment	50	43	7	13	(10, 16)	0.006	2.027	(1.216, 3.378)	0.007
		Control	40		17	-	(14, 24)				
		Total	90	66	24	<u>6</u>					
Sinus pain	0 to 5	Treatment	28		4		(7, 13)		1.926	(1.074, 3.452)	0.028
		Control Total	32 60		10 14		(9, 25)				
		Total	- 00	40	14						
Think clearly	0 to 5	Treatment	29		7		(9, 15)		2.067	(1.093, 3.909)	0.025
		Control Total	30 59		13 20		(12, 30)				
						_					
Swollen glands	0 to 5	Treatment Control	20		1		(6, 10)		2.436	(1.046, 5.676	0.039
		Total	13 33		5		(7, 13)				
					_	=					
Chest congestion	0 to 5	Treatment Control	32 27		4 10		(9, 20) (10. 32)		1.847	(1.008, 3.384)	0.047
		Total	59		14		(10.52)				
Body aches	0 to 5	Treatment	46	39	7	12	(0.17)	0.050	1.641	(0.996, 2.704)	0.052
body acries	0 10 3	Control	39		13		(9, 17) (12, 23)		1.041	(0.330, 2.704)	0.032
		Total	85		20		, , ,				
Patients with 6-10 D	 Pays Symptom Di	 uration									
		Treatment	25	9		25.5	(24.27)	0.037	0.422	(0.402.0.072)	0.094
Facility at the of			-) =				17/1 27 \	0.037	0.432	111 147 (1477)	
Feeling tired	6 to 10	Control	29		16 12		(24, 27) (13, 27)		0.432	(0.192, 0.972)	0.092

Lack of energy	6 to 10	Treatment	25	10	15	26.5	(27, 26)	0.049	0.47	(0.220, 0.996)	0.049
		Control	27	16	11	<u>20</u>	(15, 25)				
		Total	52	26	26	3.5					

Full Table for Kaplan-Meier Estimates in Patients with a WURSS-44 Q1 Score of 4-7 at Baseline


			N					
WURSS Questionnaire Item	Symptom Days	Treatment	Total	Recovered	Censored	Days	95% CI	P-value [^]
01: How sick do you feel today?	0-5d	Treatment	68	53	15	18	(13, 20)	0.050
		Control	68	42	26	21	(15, 28)	
		Total	136	95	41			
	6-10d	Treatment	32	19	13	23	(19, 27)^	0.507
		Control	31	19	12	21	(15, 27)^	
		Total	63	38	25			
	0-10d	Treatment	100	72	28	19	(16, 22)	0.197
		Control	99	61	38	21	(19, 25)	
		Total	199	133	66			
02: Cough	0-5d	Treatment	44	33	11	21	(16, 27)	0.572
		Control	38	25	13	23	(18, 28)	
		Total	82	58	24			
	6-10d	Treatment	18	11	7	25	(21, 29)^	0.429
		Control	18	12	6	18	(12, 24)^	
		Total	36	23	13			
	0-10d	Treatment	62	44	18	23	(20, 27)	0.953
		Control	56	37	19	22	(17, 27)	
		Total	118	81	37			
03: Coughing stuff up	0-5d	Treatment	17	15	2	13	(11, 28)	0.100
		Control	23	14	9	21	(13, 29)^	
		Total	40	29	11			
	6-10d	Treatment	10	10	0	11	(6, 20)	0.197
		Control	9	7	2	17	(8, 26)^	
		Total	19	17	2			
	0-10d	Treatment	27	25	2	13	(10, 20)	0.037*
		Control	32	21	11	21	(14, 27)	
		Total	59	46	13			

* p<0.05 by log-rank test for symptom days 0-5 and 6-10, and symptom-day stratified log-rank test over symptom days. 95% confidence interval (CI).

Success (recovery) criteria defined as first day of 3 consecutive days of a zero score (does not have this symptom, not at all).

Note, when median not reached, the mean (biased) is used (^). When upper confidence interval (CI) not available, 2*mean-CI_lower (^) is used. 17MAR22,T02 km


Kaplan-Meier Curve of Primary Outcome





This figure shows the "survival" probability of the primary outcomes of WURSS-44 Q1: "How sick do you feel today?" for the stratified group with symptom duration of 0-5 days at screening. "Survival" is interpreted as the endpoint not being met yet (did not recover). Subjects that did not have full recovery were censored. The difference in the median time-to-recovery (95% CI) between the two groups were estimated with the log-rank test, and its significance presented in the P-value.


Supplement 6.5


Kaplan-Meier Curves for Secondary Symptoms with Duration 0-5 days at Screening (P≤0.050)


















Kaplan-Meier Curves for Secondary Symptom Duration 6-10 days at Screening with P≤0.05



Vielight RX Plus for Covid-19
Symptom Duration 6-10 days at Screening (P≤0.050)

